Section Arrow
TTRX.NASDAQ
- Turn Therapeutics Inc
Quotes are at least 15-min delayed:2026/04/22 04:37 EDT
Pre Market
Last
 3.26
-0.09 (-2.69%)
Bid
3.26
Ask
3.5
High 3.26 
Low 3.26 
Volume
Regular Hours (Closed)
Last
 3.35
-0.03 (-0.89%)
Day High 
3.435 
Prev. Close
3.38 
1-M High
3.63 
Volume 
25.79K 
Bid
3.26
Ask
3.5
Day Low
3.2 
Open
3.4 
1-M Low
3.01 
Market Cap 
100.68M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.41 
20-SMA 3.37 
50-SMA 3.47 
52-W High 26.5 
52-W Low 2.5701 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.12/-0.15
Enterprise Value
100.72M
Balance Sheet
Book Value Per Share
0.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
Pre Market 0.2119 +0.0151 +7.67%
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
Pre Market 2.4032 -0.2868 -10.66%
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
Pre Market 0.3251 -0.0136 -4.02%
GERNGeron Corp1.5-0.06-3.85%-- 
Pre Market 1.52 +0.02 +1.33%
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Pre Market 5.5305 -0.4595 -7.67%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.